V
Valo Therapeutics
An immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines
About Valo Therapeutics
Valo Therapeutics is a clinical-stage biotechnology company developing novel oncolytic virus-based cancer immunotherapies.
Read full description
The company's main platform, PeptiCRAd, is a first-in-class cancer immunotherapy that combines an oncolytic adenovirus with peptide antigens to create a therapeutic vaccine. This approach turns the tumor into an in-situ vaccine, activating the immune system to recognize and destroy cancer cells. The platform is designed to be adaptable, allowing for the use of different tumor-specific peptides to target various types of cancer.
Valo Therapeutics is currently in Phase 1 clinical trials for its lead candidate, PeptiCRAd-1, for the treatment of solid tumors. The company is also developing a pipeline of other PeptiCRAd candidates for different cancer indications and infectious diseases.
Valo Therapeutics' business model is focused on the development and commercialization of its proprietary immunotherapy platforms. The company collaborates with other biotechnology and pharmaceutical companies to advance the development of its product candidates. Valo Therapeutics operates in the cancer immunotherapy market, a rapidly growing segment of the pharmaceutical industry.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Helsinki, Finland
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 62.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Vaccines, Spinout, Biotech and Pharma, Nordic Rising Star 2022, Hard Tech, Woman Founder, Horizon Europe, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Aug 2023
- Capital deployed
- —
- Preferred round
- POST IPO CONVERTIBLE
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2025 | $21M | $84M | CDP Venture Capital · Fondazione ENEA Tech · Indaco Venture Partners | ↗ |
| EARLY VC✓Equity / VC | Nov 2021 | $12M | $48M | Freeman Road · Mmj Group Holdings | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Valo Therapeutics is 1.1K monthly website visits, up 34.1% over the last three months. Valo Therapeutics's team declined 38.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- FRFreeman Road
Mmj Group Holdings
CDP Venture Capital
Indaco Venture Partners
Fondazione ENEA Tech
Other known investors1 additional known investor
University of Helsinki
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Valo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Valo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.